Table 1.
Demographic and clinical characteristics
| All Subjects (N=53) | SSD (n=30) | HV (n=23) | P-value | |
|---|---|---|---|---|
|
| ||||
| Age, mean (SD) | 37.4(11.0) | 36.8 (11.9) | 38.1 (10.1) | 0.69 |
| Male, n (%) | 37(69.8) | 23 (76.7) | 14(60.9) | 0.21 |
| Race | 0.68 | |||
| Black, n (%) | 26(49.1) | 15(50.2) | 11(47.8) | |
| White, n (%) | 14(26.4) | 6(20.0) | 8(34.8) | |
| Hispanic, n (%) | 4(7.6) | 3(10.0) | 1(4.4) | |
| Asian, n (%) | 2(3.8) | 1(3.3) | 1(4.4) | |
| Other, n (%) | 7(13.2) | 5(16.7) | 2(8.7) | |
| BPRS total score, mean (SD) | NA | 30.0 (9.6)[25] | NA | NA |
| Diagnoses | ||||
| Schizophrenia, n (%) | NA | 20(66.7) | NA | NA |
| Schizoaffective, n (%) | NA | 6(20.0) | NA | NA |
| Psychotic Disorder NOS, n (%) | NA | 4(13.3) | NA | NA |
| BMI, mean (SD) | 28.3(6.5)[46] | 30.0(8.1)[25] | 26.3(2.9)[21] | 0.04 |
| THC+ | 4(8.0) [50] | 4(14.3)[28] | 0(0.0)[22] | 0.07 |
| Number of Hospitalizations, median (IQR) | NA | 4(2–6.5) | NA | |
| Length of Illness, median years (IQR) | NA | 16.2(2.1–25–7) | NA | NA |
| Medications | ||||
| Antipsychotics, n (%) | NA | 22(100)[22] | NA | NA |
| Antidepressants, n (%) | NA | 9(40.9)[22] | NA | NA |
| Mood stabilizers, n (%) | NA | 3(13.6)[22] | NA | NA |
| Benzodiazepines, n (%) | NA | 8(36.4)[22] | NA | NA |
| MCCM composite score, mean(SD) | 34.0(17.0) | 25.1(16.1) | 44.5(11.3) | <0.0001 |
SSD: Schizophrenia spectrum disorder; HV: healthy volunteer; NOS: Not Otherwise Specified; BPRS: Brief Psychiatric Rating Scale; THC: tetrahydrocannabinol; MCCB: MATRICS Consensus Cognitive Battery; ^Wilcoxon rank sum test; [ ] = Number of subjects with available data if different from group total